Clinical trials: C. Difficile Infection
Clostridium Difficile Infection, Ulcerative Colitis
Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis
Fecal Microbiota Transplantation will be offered to eligible C. difficile patients (does not require Investigational New Drug designation) and to eligible ulcerative colitis or indeterminate colitis patients as Investigational…
- Conditions
- Clostridium Difficile Infection, Ulcerative Colitis, Indeterminate Colitis
- Trial name
- FMT (NCT03268213)
- Testing
- Fecal Microbial Transplantation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stony Brook University
C. Difficile Infection
Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy
The investigators found that community acquired C. diff occurs in children undergoing a colonoscopy. When they were treated their symptoms got better. But, the investigators do not know if the treatment for the C.
- Trial name
- c diff (NCT01472978)
- Testing
- metronidazole
- Where
- United States
- Sponsor
- State University of New York at Buffalo
Clostridium Difficile
Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection
C-diff infection often causes belly pain and diarrhea and can be very hard to treat with medicine. One of the possible reasons that C-diff infection is hard to treat is because there is too much "bad" bacteria in the colon.
- Trial name
- FMT (NCT02134392)
- Testing
- Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonathan Gisser
Clostridium Enterocolitis, Pseudomembranous Colitis
Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody
The purpose of this study is three fold: 1)To collect serum from patients with documented Clostridium difficile infection and test for the presence of antibody to C.
- Conditions
- Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
- Trial name
- NCT00304408
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Clostridium Difficile Infection
Protocol for Admission Toxigenic C. Difficile Surveillance
Background: Clostridioides (formerly Clostridium) difficile Infection (CDI) is a persistent healthcare issue. In the US, CDI is the most common infectious cause of hospital-onset (HO) diarrhea.
- Trial name
- NCT04014608
- Testing
- Standard Practice to Prevent Hospital Onset CDI
- Where
- United States
- Volunteers
- 148,549 people
- Sponsor
- Endeavor Health
Clostridium Difficile Infection
Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum
Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a C.
- Trial name
- NCT01704937
- Testing
- Fecal Microbiota Transplant (FMT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Bacteria Infection Mechanism
Study of Factors Influencing the Dynamics of Colonisation and Decolonisation of the Digestive Tract by Clostridioides Difficile in Infants
Clostridioides difficile (formerly C. difficile) is a bacterium found in the form of spores (a resistant form) to which patients may be exposed in a hospital environment.
- Trial name
- BBDIFF (NCT07512908)
- Testing
- cohort follow up
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
Clostridium Enterocolitis, Antibiotic-Associated Diarrhea
Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment
What is the difference between the use of one drug (Oral Metronidazole) versus the use of this same drug combined with another drug (Rifampin) in treatment of bacteria and infection-associated diarrhea in patients? This infection…
- Conditions
- Clostridium Enterocolitis, Antibiotic-Associated Diarrhea, Pseudomembranous Colitis, Pseudomembranous Enterocolitis
- Trial name
- NCT00182429
- Testing
- Metronidazole and Rifampin
- Where
- 4 sites in Canada
- Volunteers
- 100 people
- Sponsor
- McMaster University
Clostridium Difficile
C Difficile Near-patient Diagnostics
The investigators will conduct a two-period, two-intervention, cluster randomized crossover (CRXO) designed study at Foothills Hospital in Calgary, Alberta.
- Trial name
- NCT03857464
- Testing
- Near Patient Testing, SOP for C. difficile diagnostics
- Where
- 2 sites in Canada
- Volunteers
- 3,816 people
- Sponsor
- University of Calgary
Clostridium Difficile, Clostridium Difficile Infections
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo.
- Conditions
- Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
- Trial name
- RESTORATiVE303 (NCT06237452)
- Testing
- VE303
- Where
- 215 sites in United States, Australia and 22 more
- Volunteers
- 852 people
- Sponsor
- Vedanta Biosciences, Inc.
Clostridioides Difficile Infection
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
Study to evaluate the safety of ridinilazole in adolescent subjects and how ridinilazole is metabolized.
- Trial name
- Ri-CoDIFy 3 (NCT04802837)
- Testing
- Ridinilazole, Vancomycin
- Where
- 18 sites in United States
- Volunteers
- 2 people
- Sponsor
- Summit Therapeutics
Recurrent Clostridium Difficile Infection
Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Infection
The primary goal is to study participants with recurrent C. difficile infection (CDI) treated with lyophilized fecal microbiota transplantation (FMT). The safety, clinical response and relapse rate in patients will be assessed.
- Trial name
- NCT03834038
- Testing
- Lyophilized Fecal Microbiota Transplantation
- Where
- Canada
- Volunteers
- 158 people
- Sponsor
- Vancouver Island Health Authority
Clostridium Difficile, Clostridium Difficile Infection
FQ Restriction for the Prevention of CDI
This study evaluates the effectiveness of a new intervention, fluoroquinolone (FQ) Preprescription Authorization (PPA) strategy, to reduce and prevent Clostridium difficile infection (CDI) in hospital intensive care units (ICUs).
- Conditions
- Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
- Trial name
- FIRST (NCT03848689)
- Testing
- fluoroquinolone preprescription authorization, Control
- Where
- 7 sites in United States
- Volunteers
- 5,871 people
- Sponsor
- University of Wisconsin, Madison
Clostridium Difficile Infection
Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
The primary objectives of this study are to evaluate the pharmacokinetics (PK), safety, and tolerability of bezlotoxumab (MK-6072) in children aged 1 to <18 years of age with a confirmed diagnosis of Clostridium difficile…
- Trial name
- MODIFY III (NCT03182907)
- Testing
- Bezlotoxumab, Antibacterial drug treatment (ABD)
- Where
- 75 sites in United States, Argentina and 15 more
- Volunteers
- 148 people
- Sponsor
- Merck Sharp & Dohme LLC
Clostridium Difficile Colitis
Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection
The incidence of C. difficile infection (CDI) has alarmingly increased over the past several years and the affected population has expanded to include those previously at low risk, such as children.
- Trial name
- NCT01972334
- Testing
- FMT
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MemorialCare Health System
Clostridium Difficile Infection
Treatment of C. Difficile Infection With Fecal Microbiota Transplantation (FMT)
The purpose of this study is to treat children with severe, moderate, resistant or relapsing C. difficile infection and to determine the changes in the intestinal microbiome (all of the bacteria living in the intestines) in…
- Trial name
- NCT01842347
- Testing
- Fecal microbiota
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Clostridium Difficile, Clostridium Difficile Infection
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
To assess the association between Clostridium difficile (CD) toxins' serum levels and the grade of Clostridium difficile infection (CDI) severity/failure to CDI treatment and rate of recurrence.
- Trial name
- NCT03586206
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Roma Tre University
Clostridium Difficile Infection
COMBACTE-CDI Understanding the Burden of C. Difficile Infection
Clostridium difficile infection (CDI) is the most common cause of antibiotic associated diarrhoea in the western world. The infection causes significant diarrhoea, which in some cases can be serious and lead to secondary…
- Trial name
- COMBACTE-CDI (NCT03503474)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 3,240 people
- Sponsor
- University of Leeds
Clostridium Difficile
Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to Antibiotics
Purpose: To study the changes in the microbiome and stool composition in patients with Clostridium Difficile Infection (CDI) who undergo Fecal Microbiota Transplantation (FMT), along with changes in their clinical characteristics.
- Trial name
- FMT (NCT03117582)
- Testing
- Stool specimen
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of North Carolina, Chapel Hill